Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osteotech’s MagniFuse

This article was originally published in The Gray Sheet

Executive Summary

Bone graft material will launch in mid-2009 into the estimated $1.2 billion U.S. market for bone graft substitutes, Osteotech says Nov. 7. The device recently received 510(k) clearance as a bone graft substitute and bone void filler for use in the spine, pelvis and extremities. The product combines allograft bone within a polymer mesh that provides targeted and contained delivery, and avoids issues with graft site migration or irrigation often seen with other bone graft substitutes, Osteotech says. The device allows Osteotech to go head-to-head with bone morphogenetic protein products, says Osteotech President-Domestic Robert Wynalek
Advertisement

Related Content

Medtronic Expands Ortho Biologics Presence With Osteotech Acquisition
Advertisement
UsernamePublicRestriction

Register

MT026805

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel